NewsSource: EClinCloud

Five Considerations for the BYOD eCOA Model

5 min readEClinCloud Editorial Team
Article image

Source: EClinCloud. Author: eClinCloud.


Click the blue text above to follow us

Article image


In clinical research, BYOD (Bring Your Own Device) refers to the practice of participants using their own devices (such as smartphones or tablets) to collect data. For example, clinical research participants can use their own smartphones to view and complete study-related questionnaires.


During the transition from paper to electronic media for capturing clinical outcome assessment (COA) data, study teams have traditionally provided devices to participants to collect electronic clinical outcome assessment (eCOA) data.


In recent years, to simplify trial participation, the BYOD model has been seen as an easier way for participants to complete patient-reported outcomes (PROs) in clinical trials. As sponsors and contract research organizations (CROs) also recognize the advantages of BYOD for clinical trial participation along with improved technology availability, a growing number of sponsors and CROs are interested in adopting a BYOD approach for conducting clinical trials.


Article image

Below, we explore several questions and considerations related to BYOD.

01
Do patients prefer BYOD?

Although there is no definitive answer to this question, two published BYOD studies offer some insights. Byrom et al. (2018) reported that in a study of 155 patients with chronic pain, 45% felt it would be more convenient to use their own device, whereas 15% preferred using a device provided by the trial organization (a provisioned device), and 40% had no preference. In addition, Newton et al. (2018) reported a study of 64 patients with COPD, which showed no clear device preference among patients, with 50.9% preferring BYOD and 45.6% preferring a provisioned device. In the second study, the most common reason for preferring a provisioned device was that it was "dedicated" to the study, whereas the main reason for preferring BYOD was the "convenience" of carrying a single device.


Is BYOD acceptable to patients, including those who prefer a provisioned device? In Byrom's study, 94% of patients (146 of 155 patients) indicated that they would "definitely" or "probably" download an app onto their own mobile device for an upcoming clinical trial. This level of acceptance is also reflected in the high BYOD adoption rates seen in studies supported by Signant Health—80% used BYOD, and 20% chose a device provided by the trial organization.


02
Does BYOD improve completion rates?

Completion rates between BYOD and provisioned-device users are generally very similar, though the trend appears to favor BYOD. For example, in a large BYOD study involving more than 10000 patients aged 50 to 85 years across more than 20 countries, daily diary completion rates were 85% for BYOD users and 84% for provisioned-device users.


Signant provides provisioned devices for patients in BYOD studies who do not have or are unwilling to use their own smartphones. Although this may not be a randomized comparison, it does provide useful information to help us understand completion between patients using BYOD and those using provisioned devices.


03
What support do study sites need when implementing BYOD?


The training materials and patient setup guides Signant provides to clients can practically assist study sites implementing BYOD. After visiting a group of study sites using Signant's BYOD solution, we learned that with Signant's support, these study sites felt BYOD did not take more time than providing provisioned devices, and their teams did not perceive BYOD as adding burden. However, they noted that it is important to remind patients before their visit to confirm they can log in to their phone's app store to download the app smoothly.


This feedback has changed the conventional perception that BYOD is a more burdensome process for study sites requiring more patient support and technical troubleshooting.


04
Do regulatory agencies accept BYOD data?


Until recently, there had been no reported cases in the industry of successful drug applications using BYOD data. Understandably, this raised client concerns about whether regulatory agencies would accept BYOD data. However, this year the industry's largest BYOD study—for COVID-19 vaccine development involving more than 43000 participants—collected primary safety data through reactogenicity diaries completed by patients using the Signant platform. The vaccine received emergency use authorization from agencies worldwide, including the FDA, EMA, and MHRA.


For future studies, this is an encouraging indicator that reinforces our scientific conviction that data collected via BYOD can be just as credible and reliable as data collected using provisioned devices.


05
Is evidence needed to prove the validity of BYOD?


For new BYOD studies, as long as best-practice principles for ePRO design are followed, researchers are likely to rely on existing evidence without needing to conduct specific qualitative or quantitative studies. A reasonable approach, for example, is to compile a summary of supporting published evidence and provide proof that best practices were applied, such as an ePRO screening report.


The reason behind this is the growing body of evidence supporting the measurement equivalence of patient-reported outcome data collected using different modes of administration and various electronic devices. The first formal BYOD equivalence study strongly supported full measurement equivalence across more than 150 patients using different devices and instruments comprising common response scale types (verbal rating scales, numeric rating scales, and visual analog scales). This was shortly thereafter confirmed by a second study conducted by the Critical Path Institute.



EClinCloud, Signant's exclusive strategic partner in Greater China
Delivering comprehensive local support and after-sales service to international standards

Headquartered in Pennsylvania, United States, Signant has more than 2,000 employees across three continents globally.


Focused on the complex field of neurology, it has supported thousands of clinical trials worldwide for over 20 years.


It is a global leader in eCOA & endpoint assessment, with annual revenue exceeding $400 million.



EClinCloud

With the mission of "bringing effective treatments to patients through technological innovation," EClinCloud is a China-based, globally serving healthcare and life sciences technology company. Through EClinCloud's seamlessly integrated end-to-end unified platform (including scale management, linguistic validation, study design, eCOA, eConsent, EDC, CTMS, eTMF, and more) and precision medical evaluation systems across therapeutic areas (oncology, neurology, cardiology, pulmonology, dermatology, and more), it is building a globally leading, patient-centric integrated SaaS cloud platform supporting clinical evidence—helping well-known domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate drug and device launches, and benefit countless patients.

Article image


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.